These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27603206)

  • 41. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort.
    Gryn SE; Teft WA; Kim RB
    Pharmacogenet Genomics; 2014 Jul; 24(7):367-9. PubMed ID: 24915025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
    Ramón y Cajal T; Altés A; Paré L; del Rio E; Alonso C; Barnadas A; Baiget M
    Breast Cancer Res Treat; 2010 Jan; 119(1):33-8. PubMed ID: 19189210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
    Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
    Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.
    Hertz DL; Rae JM
    Pharmacogenomics; 2016 Jun; 17(8):823-6. PubMed ID: 27249031
    [No Abstract]   [Full Text] [Related]  

  • 48. The Underrated Risks of Tamoxifen Drug Interactions.
    Hansten PD
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):495-508. PubMed ID: 29637493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individualization of tamoxifen treatment for breast carcinoma.
    Binkhorst L; van Gelder T; Mathijssen RH
    Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
    Kaplan M; Mahon SM
    Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
    Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
    Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.
    Jung JA; Lim HS
    Pharmacogenomics; 2014 Jan; 15(1):49-60. PubMed ID: 24329190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
    Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
    J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
    Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
    Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.
    Reis SS; Carvalho AS; Fernandes R
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31284530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
    Del Re M; Citi V; Crucitta S; Rofi E; Belcari F; van Schaik RH; Danesi R
    Pharmacol Res; 2016 May; 107():398-406. PubMed ID: 27060675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical
    Mulder TAM; de With M; Del Re M; Danesi R; Mathijssen RHJ; van Schaik RHN
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor.
    Goetz MP
    Oncology (Williston Park); 2009 Dec; 23(14):1233-4, 1236. PubMed ID: 20120835
    [No Abstract]   [Full Text] [Related]  

  • 60. Profiling of pharmacogenomic variants in
    Alsulaiman A; Chu H; Al-Jumaan M; Alyahya M; Marzooq YA; Almulhim F; Vatte C; Alnimer A; Almuhanna A; Al-Ali A; AlDubayan SH
    Pharmacogenomics; 2023 May; 24(7):411-423. PubMed ID: 37222147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.